Skip to main content

Table 2 MSSES Function and Control scores in non-persistent, persistent, persistent non-adherent, and persistent adherent patients at baseline

From: Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study)

  MSSES Function
Non-persistent (n = 58) Persistent (n = 131) Persistent non-adherent (n = 19) Persistent adherent (n = 112)
Mean (SD) (min.-max.) 689 (173)* (280–900) 752 (156)* (90–900) 715 (182) (240–900) 758 (151) (90–900)
  MSSES Control
Non-persistent (n = 58) Persistent (n = 131) Persistent and non-adherent (n = 19) Persistent and adherent (n = 112)
Mean (SD) (min.-max.) 491 (192)# (130–900) 568 (178)# (90–900) 560 (140) (210–780) 570 (185) (90–900)
  1. MSSES Multiple Sclerosis Self-Efficacy Scale, min. minimum, max., maximum
  2. *p = 0.0087, # p = 0.0042